Fewer business results this morning, with the earnings season coming to an end, but news is filled with announcements of all kinds, with Moderna’s successful vaccine trial, the buyout of Nets by Nexi or the buyout of BBVA's assets in the United States by PNC.
Dermapharm: the German laboratory confirmed its 2020 forecast after quarterly results up 11.5% in revenues and 4.4% in EBITDA. It signed an agreement with BioNTech for the production of its vaccine against Covid.
Sonova: the half-year results for the 2020/2021 financial year are higher than expected, albeit significantly lower than a year ago, but the annual forecast is confirmed.
JD.com reported Monday that revenues were up 29% in the third quarter, with online orders for key products still strong even after the lifting of coronavirus restrictions in China.
In other news:
Moderna gains 17 percent in pre-market trading after announcing that its candidate vaccine was 94.5 percent effective against Covid-19.
Johnson & Johnson on Monday launched a clinical trial of its COVID-19 candidate vaccine given as a double dose to determine whether a second dose prolongs its effects.
Qualcomm received the green light from U.S. authorities to sell 4G chips to Chinese Huawei, an exception to the restrictions imposed by Washington on the sale of strategic technologies to Huawei.
The Italian company Nexi is buying the Danish company Nets for €6 billion in shares.
Information from Bloomberg suggests that Nissan is considering reducing its 34% stake in Mitsubishi Motors. Nissan has denied the existence of such a project.
Vodafone could float its relay antennas on the stock market and raise $4 to $5 billion in 2021, according to Bloomberg.